Scholars@Duke
Search form
Search
Advanced Search
Support
Index
Subscribe to Announcements
Menu
Search
Home
People
Schools / Institutes
Research
About
Home
People
Schools / Institutes
Research
An open label, phase 1/2 safety, pharmacokinetic, and proof-of-concept study of ARN-509 in patients with progressive
Administered By
Duke Cancer Institute
Contributors
Berry, William Rosser
Principal Investigator
Start/End
October 1, 2014 - December 31, 2017